Feds commit over $199M to Resilience Biotechnologies Inc.
by CM Staff
This investment will help Resilience Biotechnologies Inc. increase its manufacturing and fill-finish capacity for a number of vaccines and therapeutics.
MISSISSAUGA — On May 18, François-Philippe Champagne, Minister of Innovation, Science and Industry, announced an investment of $199.16 million in Resilience Biotechnologies Inc.
This investment will support a $401.52-million project that will hopefully help to develop Canada’s medical countermeasures to COVID-19 and strengthen Canada’s emergency preparedness for future pandemics.
This investment will help Resilience Biotechnologies Inc. increase its manufacturing and fill-finish capacity for a number of vaccines and therapeutics, including for those that use novel technology such as mRNA and that are now being deployed to fight COVID-19. Once completed, the company’s Mississauga facility is expected to allow for the manufacturing of approximately 112 million to 640 million doses of mRNA vaccines per year.
This expansion will further expand Resilience Biotechnologies Inc.’s presence in Canada, with clinical and commercial manufacturing and aseptic fill-finish capabilities for critical vaccines and therapeutics. With this investment, Resilience Biotechnologies Inc. will create and maintain 500 full-time jobs in Canada and create 50 co-op positions.
The federal government’s Budget 2021 proposes a total of $2.2 billion to build on the progress already made towards a stronger biomanufacturing sector, and this announcement is a part of that commitment.
“The Government of Canada’s top priority is to protect the health and safety of Canadians. Today’s contribution to Resilience Biotechnologies Inc. is another important step to support Canada’s leadership in the life sciences sector and to build its pandemic preparedness. These investments are also creating well-paying jobs and helping to grow Canada’s life sciences ecosystem as an engine for our economic recovery.” sadi François-Philippe Champagne, Minister of Innovation, Science and Industry.
Resilience Biotechnologies Inc. is a wholly owned subsidiary of National Resilience Inc. located in Mississauga, Ontario, specializing in the development and manufacture of clinical and commercial complex biologics, vaccines and aseptic fill-finish as a contract development and manufacturing organization (CDMO).